1. Change the title name to the official tarcker name -- > “antibody therapeutics tracker” and any occurrence afterwards in the main article (Weihan)
2. Abstract Insert web address into the abstract after the official name of the tracker.(Weihan)
3. The last sentence of abstract, specify US and China is the two leading country according to the total number of candidates in development reported as of mid-July ( insert figure number, talk to figure) (Weihan)
4. I was broken out of the meeting here for 3 mins, is there anything important here?
5. Shorten the automation part a bit, maybe gear the language more towards non-programmers(Xin).
6. Change the Junshi JS016, changed it to be “assumed to be JS016”(Weihan)
7. Lilly LY-CoV555, double check if it has another name. In the first time we mention it, including all the name. Can we find a citation for this drug, Doesn’t have to be a paper, could be a news report who has a doi, if no citation, just put a link in the text. Put a news report link also for other drugs(TY027) that do not currently have any reference. Include the data of submission as the date of accession of the press news release(Lifei)
8. We need to give the clinicaltrial.gov NCT numbers for all the drugs we mention. Put NCT number after the clinical trial status of that drug. Put the NCT number in the place where we talk about the clinical trial status of the drug Eg.“Phase 1(NCT: xxxxxx)” (Lifei)
9. Fig 2A:
   1. explains what the “others” categories are, eg. Give 10 examples what they are.(Lifei)
   2. Move the one cow SARS-CoV-2 targets into the S protein.(Weihan)
   3. Put a \* next to the 3 remaining SARS-CoV-2 and explain in the legend what are they(Lifei)
10. Fig 2B:
    1. explain in the MAb,are they mostly human full length IgG. include mostly human antibody including some chimeric Abs. Also include in the legend what are in the “others”(Lifei)
    2. Are all the fusion protein Fc fusion? If so we can just call it Fc fusion(Lifei,Weihan)
11. Think of a criteria to define Discovery and preclinical status, be prepared to answer questions, no need to put in paper. Jan’s advice to include in the legend: preclinical refer to the early candidates whose developmental entity have said they have a time line to move into clinical stage, everything else are discovery. (Lifei)
12. Table 2: Put a table summarizing the antibodies we mentioned in the article: Antibody name , target epitope ,NCT number, reference link etc.(Lifei)
13. Cover image: two pie charts: clinical status and targets, round the pct numbers. Add the logo of the tracker in the bannerIn the targets, the S protein uses red, others uses different shades of blue or grey. In the clinical status pie chart, still use continuous scale, Xin provides color choices(Weihan, Xin).